Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in Interest ReceivablesChange in Net LoansChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Cash from Financing Activities (2016 - 2025)

iBio (IBIO) has disclosed Cash from Financing Activities for 14 consecutive years, with $8.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 5879.61% to $8.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $64.7 million, a 265.66% increase, with the full-year FY2025 number at $8.9 million, down 63.55% from a year prior.
  • Cash from Financing Activities was $8.8 million for Q4 2025 at iBio, down from $46.7 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $46.7 million in Q3 2025 to a low of -$6.0 million in Q4 2021.
  • A 5-year average of $4.6 million and a median of $2.0 million in 2023 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: tumbled 117.15% in 2021, then surged 28930.25% in 2025.
  • iBio's Cash from Financing Activities stood at -$6.0 million in 2021, then surged by 49.41% to -$3.0 million in 2022, then skyrocketed by 231.57% to $4.0 million in 2023, then tumbled by 103.8% to -$152000.0 in 2024, then skyrocketed by 5879.61% to $8.8 million in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Cash from Financing Activities are $8.8 million (Q4 2025), $46.7 million (Q3 2025), and $8.2 million (Q2 2025).